A New Era in Vaccine Technology: DNA Origami Platform Emerges as Potent Alternative to mRNA for Global Health Challenges.

The unprecedented global health crisis ignited by the COVID-19 pandemic propelled messenger RNA (mRNA) vaccines from a nascent scientific concept into a frontline defense, fundamentally reshaping public health strategies worldwide. Following an accelerated development and rigorous clinical trial process, the first COVID-19 mRNA vaccine was administered on December 8, 2020, marking a pivotal moment in medical history. Subsequent sophisticated modeling studies, often conducted by institutions like the World Health Organization and the Centers for Disease Control, have conservatively estimated that these groundbreaking vaccines prevented at least 14.4 million deaths globally within their initial year of deployment, a testament to their profound impact on human mortality and morbidity. This monumental success ignited a fervent acceleration in scientific research, inspiring an expansive global effort to adapt mRNA technology for a multitude of other infectious diseases. Currently, numerous clinical trials are underway, targeting a diverse array of pathogens including the influenza virus, Respiratory Syncytial Virus (RSV), Human Immunodeficiency Virus (HIV), Zika virus, Epstein-Barr virus, and even tuberculosis bacteria, underscoring the broad potential envisioned for this platform. However, the rapid, real-world deployment of COVID-19 mRNA vaccines also brought to light several important limitations and practical challenges, signaling a critical need for continuous innovation and the exploration of complementary or entirely new vaccine strategies to bolster global pandemic preparedness.

The Dual Legacy of mRNA Vaccines: Triumph and Technical Hurdles

The journey of mRNA vaccines, from theoretical promise to widespread application, represents one of the most remarkable scientific achievements of the 21st century. Before 2020, mRNA technology had been under investigation for decades, primarily for cancer immunotherapy and rare genetic diseases, but it had never been approved for an infectious disease in humans. The urgent demand for a COVID-19 vaccine, however, catalyzed an extraordinary collaborative effort that compressed years of research and development into mere months. This rapid translation was facilitated by the inherent flexibility of mRNA technology, which allows for quick adaptation to new viral strains by simply altering the genetic sequence encoding the target antigen. The high efficacy rates reported in initial trials—often exceeding 90% against symptomatic infection—and their robust ability to prevent severe disease, hospitalization, and death, quickly cemented their status as a cornerstone of the global pandemic response.

Despite these unparalleled successes, the experience with COVID-19 mRNA vaccines illuminated several significant performance and production challenges that warrant further innovation. One primary concern is the observed variability in the immune protection generated by these vaccines, which can differ widely from person to person due to individual genetic factors, pre-existing immunity, and other biological nuances. Furthermore, the duration of this protective immunity is not indefinite, necessitating booster shots to maintain adequate defense. This issue is compounded by the relentless evolutionary pressure on SARS-CoV-2, which continually produces new variants capable of partially evading existing immune defenses. The Omicron variant, for instance, demonstrated a significant degree of immune escape, requiring vaccine manufacturers to develop updated, bivalent formulations to target these newer strains, thereby adding complexity to vaccine development and deployment.

Beyond the immunological aspects, practical challenges associated with mRNA vaccine manufacturing and distribution proved substantial. The production process for mRNA vaccines is inherently complex and expensive, involving intricate steps for synthesizing high-quality mRNA and encapsulating it within lipid nanoparticles (LNPs). Controlling the precise number of mRNA molecules packaged into these LNPs remains a difficult technical hurdle, impacting consistency and yield. Perhaps the most widely recognized logistical obstacle is the stringent cold-chain requirement. Early mRNA vaccines, such as Pfizer-BioNTech’s Comirnaty, required ultra-cold storage at temperatures between -70°C and -80°C, while Moderna’s Spikevax initially required -20°C. These extreme temperature requirements necessitated specialized freezers, sophisticated transportation logistics, and significant infrastructure investments, especially challenging for low- and middle-income countries with limited resources. This "cold chain" significantly increased distribution costs and restricted access, exacerbating global vaccine inequity. Moreover, the LNP delivery system, while effective, can sometimes lead to unintended off-target effects, including localized inflammatory responses or, in rare cases, systemic reactions. Overcoming these multifaceted limitations is not merely an academic exercise; it is crucial for enhancing the world’s preparedness and responsiveness to future infectious disease threats, ensuring more equitable and efficient vaccine deployment on a global scale.

DoriVac: A DNA Origami Nanotechnology Platform Emerges

In a concerted effort to address the identified limitations of current vaccine technologies and pave the way for a new generation of immunizations, a multidisciplinary team spanning institutions like the Wyss Institute at Harvard University, Dana-Farber Cancer Institute (DFCI), and their partner organizations has unveiled a novel approach. They have leveraged a cutting-edge DNA origami nanotechnology platform, christened DoriVac, which functions uniquely as both a potent vaccine antigen presentation system and a built-in adjuvant. This innovative dual functionality represents a significant departure from conventional vaccine designs, which typically require separate components for antigen delivery and immune stimulation.

The fundamental principle behind DoriVac lies in DNA nanotechnology, a field that manipulates DNA molecules to self-assemble into precise, predetermined 3D nanostructures. In the case of DoriVac, researchers have engineered tiny, square DNA nanostructures that act as a highly versatile chassis. One side of this nanostructure is meticulously designed to display immune-stimulating adjuvant molecules, arranged at carefully controlled nanometer distances. This precise spatial arrangement is critical, as the presentation geometry of adjuvants can profoundly influence the strength and quality of the immune response. The opposite side of the DoriVac platform presents selected antigens, such as peptides or proteins derived from pathogens or tumors. This unprecedented level of control over vaccine composition and the ability to program immune recognition at a molecular level within targeted immune cells are among DoriVac’s most compelling advantages.

The research team specifically designed DoriVac vaccines to target a conserved peptide region known as HR2, found in the spike proteins of several highly pathogenic viruses, including SARS-CoV-2, HIV, and Ebola. Targeting such conserved regions is a strategic move aimed at developing broad-spectrum vaccines that are less susceptible to viral mutations, potentially offering more durable protection against evolving threats. In initial preclinical studies conducted in mice, the SARS-CoV-2 HR2 DoriVac vaccine successfully triggered robust immune responses, encompassing both antibody-driven (humoral) activity and T cell-driven (cellular) immunity. The breadth and strength of these responses, crucial for long-term protection, were highly encouraging.

Crucially, the team extended their investigations beyond traditional animal models by testing the DoriVac vaccine in a preclinical human model. This involved utilizing the Wyss Institute’s sophisticated microfluidic human Organ Chip technology, specifically a human lymph node-on-a-chip (human LN Chip). This advanced in vitro system accurately simulates aspects of the human immune system, offering a more predictive platform for evaluating vaccine candidates than conventional cell cultures or even some animal models. Within this human-relevant system, the SARS-CoV-2 HR2 DoriVac vaccine also generated strong antigen-specific immune responses in human cells, further bolstering confidence in its translational potential. When directly compared with traditional SARS-CoV-2 mRNA vaccines delivered through lipid nanoparticles, a DoriVac vaccine engineered to carry the same spike protein variant produced a similarly strong immune activation in these human models. However, the DNA origami vaccine exhibited distinct advantages in terms of stability, ease of storage, and manufacturing simplicity. These pivotal findings, highlighting DoriVac’s versatility and potential, were meticulously reported in the esteemed scientific journal Nature Biomedical Engineering.

From Cancer Research to Global Pandemic Response: A Timeline of Innovation

The DoriVac platform’s journey is a testament to the serendipitous intersections of fundamental research and urgent societal needs. The initial conceptualization and development of DoriVac emerged from the pioneering work of William Shih, Ph.D., a Wyss Institute Core Faculty member and Professor at Harvard Medical School and DFCI, whose group has been at the forefront of DNA nanotechnology. In 2024, Shih’s team, in collaboration with Dana-Farber, formally introduced DoriVac as a DNA nanotechnology-based vaccine platform with expansive potential applications. Yang (Claire) Zeng, M.D., Ph.D., who spearheaded much of this foundational effort, demonstrated DoriVac’s capacity to precisely present immune-stimulating adjuvant molecules to cells at the nanoscale, a critical feature distinguishing it from other vaccine technologies.

Early studies in tumor-bearing mice provided compelling evidence of DoriVac’s superior immunogenicity. These preclinical trials showed that DoriVac vaccines consistently produced stronger immune responses against cancer antigens compared to versions lacking the DNA origami structure, thereby validating the platform’s core design principle of enhanced adjuvant activity. As Zeng, who is also a first and co-corresponding author on the new study and now cofounder and CEO/CTO of DoriNano, recalls, the persistent grip of the COVID-19 pandemic during DoriVac’s development naturally raised a crucial question: "whether DoriVac’s superior adjuvant activity could also be leveraged in infectious disease settings." This strategic pivot underscored the platform’s adaptability and the researchers’ commitment to addressing pressing global health challenges.

To explore this compelling hypothesis, Zeng and co-first author Olivia Young, Ph.D., a former graduate student in Shih’s group, initiated a collaborative effort with Donald Ingber’s team at the Wyss Institute. Ingber’s lab is renowned for its innovative antiviral research, which integrates AI-driven and multiomics approaches with advanced microfluidic human Organ Chip systems. Working alongside co-first author Longlong Si, Ph.D., a former postdoctoral researcher in Ingber’s lab, the interdisciplinary team developed DoriVac vaccines specifically targeting SARS-CoV-2, HIV, and Ebola. These vaccines were designed to present the HR2 peptides, selected for their role as conserved antigens within the respective viral spike proteins, offering a promising avenue for broad-spectrum protection.

The subsequent analysis of immune responses provoked by these initial DoriVac vaccines in mice yielded several highly encouraging observations. Zeng noted "significantly greater and broader activation of humoral and cellular immunity across a range of relevant immune cell types than what the origami-free antigens and adjuvants could produce." Specifically, the studies revealed an increased proliferation of antibody-producing B cells, enhanced activation of antigen-presenting dendritic cells (DCs), and a boost in both antigen-specific memory and cytotoxic T cell types. These cellular components are absolutely vital for generating robust and long-lasting protective immunity, with the SARS-CoV-2 HR2 vaccine demonstrating particularly strong results in this regard.

Bridging the Translational Gap: From Mouse Models to Human Organ Chips

A persistent and formidable challenge in vaccine development is the inherent disparity between immune responses observed in animal models, particularly mice, and those that ultimately occur in humans. This translational gap has historically led to numerous promising treatments failing during later-stage clinical trials, representing significant investments in time, resources, and scientific effort. To mitigate this risk and enhance the predictive power of their preclinical assessments, the Wyss Institute team judiciously employed their advanced human lymph node-on-a-chip (human LN Chip) system.

This innovative microfluidic platform, further advanced by co-first author Min Wen Ku and co-corresponding author Girija Goyal, Ph.D., Director of Bioinspired Therapeutics at the Wyss Institute, offers a sophisticated in vitro mimicry of human physiological conditions relevant to immune responses. By culturing human immune cells within a microfluidic environment that recapitulates the architecture and fluid dynamics of a human lymph node, the researchers could observe antigen-specific immune cell profiles and activities that are far more likely to reflect actual human outcomes. Within this human LN Chip system, the SARS-CoV-2-HR2 DoriVac vaccine demonstrated clear activation of human dendritic cells (DCs) and significantly boosted their production of inflammatory cytokines—key signaling molecules that orchestrate immune responses—compared with origami-free vaccine components. Furthermore, the DoriVac vaccine led to an increased number of CD4+ and CD8+ T cells, both of which are crucial for a multitude of protective immune functions, including direct pathogen killing and coordinating other immune cells. This compelling evidence from a human-relevant model strongly supports the platform’s potential for effective human use.

Donald Ingber, M.D., Ph.D., a co-corresponding author on the study and the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, as well as the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences, emphasized the significance of this approach. He stated, "The predictive capabilities of human LN Chips gave us an ideal testing ground for DoriVac vaccines and the induced, antigen-specific immune cell profiles and activities very likely reflect those that would occur in human recipients of the vaccines. This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines and create a new testbed for future vaccine developments." This strategic integration of advanced human organ-on-chip technology underscores a paradigm shift in preclinical validation, aiming to accelerate the development of safer and more effective vaccines.

DoriVac Versus mRNA: A Head-to-Head Comparison

To rigorously evaluate DoriVac’s competitive standing against the current gold standard, the research team conducted a direct head-to-head comparison with established mRNA vaccines. Led by Zeng and co-author Qiancheng Xiong, the study involved a DoriVac vaccine presenting the full SARS-CoV-2 spike protein. This was directly pitted against commercially available Moderna and Pfizer/BioNTech mRNA lipid nanoparticle (LNP) vaccines, both of which encode the identical spike protein antigen.

Using a standard booster approach in mice, the researchers meticulously assessed the immune responses generated by both vaccine types. The results were highly encouraging: both the DoriVac platform and the mRNA-LNP vaccines produced strikingly similar antiviral T cell and antibody-producing B cell responses. This finding is profoundly significant, as it demonstrates DoriVac’s ability to elicit comparable levels of immunogenicity to the highly effective mRNA vaccines, without the inherent complexities and limitations of the latter.

William Shih further elaborated on DoriVac’s distinct advantages, stating, "This underscored DoriVac’s potential as a DNA nanotechnology-enabled, self-adjuvanted vaccine platform. But DoriVac vaccines have a number of other advantages: they don’t have the same cold-chain requirements as mRNA-LNP vaccines do and thus could be distributed much more effectively, especially in under-resourced regions; and they could overcome some of the enormous manufacturing complexities of LNP-formulated vaccines, to name two major ones." The elimination of ultra-cold storage requirements represents a monumental leap forward for global vaccine distribution. It promises to drastically reduce logistical hurdles and costs, making advanced vaccines accessible to remote and underserved populations that were previously marginalized by the cold-chain demands of mRNA vaccines. The simpler manufacturing process also holds the potential for greater scalability and reduced production expenses, fostering a more robust and equitable global vaccine supply. Furthermore, recent independent studies conducted at DoriNano have indicated that the DoriVac platform exhibits a promising safety profile, an essential prerequisite for any new vaccine technology.

Broader Impact and Future Horizons

The emergence of the DoriVac platform carries profound implications for global health and future pandemic preparedness. Its inherent stability, simplified manufacturing, and precise control over immune stimulation position it as a critical tool in the global arsenal against infectious diseases. By overcoming the cold-chain dependency and manufacturing complexities associated with mRNA vaccines, DoriVac offers a viable pathway to greater vaccine equity, ensuring that effective immunizations can reach every corner of the world, regardless of infrastructure limitations. This is particularly vital for developing nations, which often bear the brunt of infectious disease outbreaks and faced significant challenges in accessing COVID-19 mRNA vaccines due to logistical constraints.

Beyond its immediate application to SARS-CoV-2, the versatility of the DNA origami platform means it can be readily adapted to target a wide spectrum of pathogens, from emerging viruses to antibiotic-resistant bacteria. The ongoing research targeting influenza, RSV, HIV, Zika, Epstein-Barr virus, and tuberculosis bacteria underscores its broad potential. The ability to precisely present conserved antigens, as demonstrated with the HR2 peptide, also opens avenues for developing pan-vaccines that offer protection against multiple strains or even entire families of viruses, reducing the need for constant updates.

The path forward for DoriVac will involve rigorous human clinical trials to confirm its safety and efficacy in diverse populations. The formation of DoriNano, co-founded by Yang Zeng, highlights the commitment to translating this groundbreaking technology from the laboratory bench to clinical application, signaling serious intent for commercialization and widespread deployment. This innovation is not just about creating another vaccine; it is about establishing a foundational technology that can fundamentally alter how the world responds to and mitigates future infectious disease threats, fostering a more resilient and equitable global health landscape.

This ambitious research was made possible through significant financial backing from a consortium of prestigious institutions and foundations, including the Director’s Fund and Validation Project program of the Wyss Institute; the Claudia Adams Barr Program at DFCI; the National Institutes of Health (U54 grant CA244726-01); the US-Japan CRDF global fund (grant R-202105-67765); the National Research Foundation of Korea (grants MSIT, RS-2024-00463774, RS-2023-00275456); the Intramural Research Program of the Korea Institute of Science and Technology (KIST); and the Bill and Melinda Gates Foundation (INV-002274). The extensive list of contributing authors, including Sylvie Bernier, Hawa Dembele, Giorgia Isinelli, Tal Gilboa, Zoe Swank, Su Hyun Seok, Anjali Rajwar, Amanda Jiang, Yunhao Zhai, LaTonya Williams, Caleb Hellman, Chris Wintersinger, Amanda Graveline, Andyna Vernet, Melinda Sanchez, Sarai Bardales, Georgia Tomaras, Ju Hee Ryu, and Ick Chan Kwon, further attests to the collaborative spirit and multidisciplinary expertise that brought this groundbreaking scientific endeavor to fruition.